Top Story

Durable response to T-VEC, GM-CSF linked to longer OS

April 25, 2015

NEW YORK — Patients with unresected stage IIIB, stage IIIc or stage IV melanoma who achieved durable response to either talimogene laherparepvec or granulocyte-macrophage colony–stimulating factor demonstrated longer OS than those who did not achieve a durable response, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.

In the randomized phase 3 OPTiM trial, researchers compared talimogene laherparepvec (T-VEC, Amgen) — a systemically active oncolytic immunotherapy derived from herpes simplex virus type-1 — with GM-CSF in patients with unresectable stage IIIb, stage IIIc or stage IV melanoma.

Meeting News Coverage

Algorithm predicts HCC in patients with cirrhosis

April 25, 2015
VIENNA — A new algorithm accurately predicted hepatocellular carcinoma among a cohort of patients with cirrhosis, according to a study presented at the 2015…
Cover StoryPublication Exclusive

Expansion of ‘Right to Try’ legislation raises ethical, safety concerns

HemOnc Today, April 25, 2015
Early access to experimental drugs has historically been reserved for patients enrolled on clinical trials.In 2009, the FDA revamped its 1980’s expanded access program…
Hemant Murthy, MD In PracticePublication Exclusive

State of the science: High-priority transplant trials for nonmalignant disease

HemOnc Today, April 25, 2015
Hemant Murthy, MD; William Wood, MD
Last June, we launched a series of columns in HemOnc Today intended to discuss high-priority proposals that emerged from the 2014 Blood and Marrow Transplant Clinical…
FDA News

FDA approves Cyramza for mCRC

April 24, 2015
The FDA today announced the approval of ramucirumab for use in combination with FOLFIRI chemotherapy for the treatment of certain patients with metastatic colorectal…
More News Headlines »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
VIDEO: Immunotherapy developments show 'real promise' in melanoma

VIDEO: Immunotherapy developments show 'real promise' in melanoma

April 16, 2015
Steven J. O’Day, MD, discusses new advancements in immunotherapies and checkpoint inhibitors — such as…
More »
CME CNE
Stem Cell Transplant for AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 3 Stem Cell Transplant for MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »
morganatic-roan
morganatic-roan